Last reviewed 2026-04-23 · How we verify

Placebo + ADT

Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells.

Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells. Used for Prostate cancer.

At a glance

Mechanism of action

ADT works by targeting the androgen receptor, which is a protein that helps regulate the growth of prostate cancer cells. By blocking the androgen receptor, ADT can slow or stop the growth of prostate cancer cells. In the context of this treatment, the placebo serves as a control group to compare the effectiveness of ADT.

Approved indications

• Prostate cancer

Common side effects

• Hot flashes
• Fatigue
• Loss of libido
• Erectile dysfunction
• Osteoporosis

Key clinical trials

• Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (PHASE3)
• A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) (PHASE4)
• Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (NA)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.